UK's chief regulator speaks out on communication agenda
This article was originally published in Clinica
Executive Summary
How is the UK's Medicines and Healthcare products Regulatory Agency (MHRA) going to improve its communications with stakeholders, and particularly the medical devices industry, after criticism that it has not been accessible enough since the medicines and medical devices authorities merged in April 2003 and that it has lost its dedicated figurehead for devices? Amanda Maxwell interviewed MHRA chief executive Professor Kent Woods to find out
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.